BOL 303259-X

a lanatoprost prodrug, nitric oxide donor, and PGF2alpha agonist

Also Known As:

BOL-303259-X; BOL303259-X; NCX 116; NCX-116; NCX116; PF 3187207; PF-3187207; PF3187207; latanoprostene bunod

Networked: 28 relevant articles (8 outcomes, 9 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Lipids: 114793
- Fatty Acids: 27405
  - Unsaturated Fatty Acids: 8236
    - Eicosanoids: 3262
      - Prostaglandins: 17100
        Synthetic Prostaglandins: 823
        Synthetic Prostaglandins F: 2
        BOL 303259-X: 28
Biological Factors: 2472
- Inflammation Mediators: 1113
  - Synthetic Prostaglandins: 823
    - Synthetic Prostaglandins F: 2
      - BOL 303259-X: 28
  - Autacoids: 276
    - Eicosanoids: 3262
      - Prostaglandins: 17100
        Synthetic Prostaglandins: 823
        Synthetic Prostaglandins F: 2
        BOL 303259-X: 28

Experts

1.	Weinreb, Robert N: 7 articles (01/2022 - 06/2015)
2.	Vittitow, Jason L: 4 articles (01/2018 - 06/2015)
3.	Kaufman, Paul L: 3 articles (01/2018 - 06/2015)
4.	Scassellati Sforzolini, Baldo: 3 articles (08/2016 - 06/2015)
5.	Hoy, Sheridan M: 2 articles (05/2018 - 01/2018)
6.	Martin, Keith R: 2 articles (01/2018 - 08/2016)
7.	Vittitow, Jason: 2 articles (05/2016 - 11/2015)
8.	Araie, Makoto: 2 articles (01/2016 - 11/2015)
9.	Desai, Sujata J: 1 article (07/2022)
10.	Koethe, Benjamin: 1 article (07/2022)

Related Diseases

1.	Open-Angle Glaucoma (Glaucoma, Open Angle) 12/01/2020 - "Retrospective Chart Review on Real-World Use of Latanoprostene Bunod 0.024% in Treatment-Naïve Patients with Open-Angle Glaucoma." 01/01/2018 - "Latanoprostene bunod (LBN) is a topical ophthalmic therapeutic for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension (OHT). " 01/01/2016 - "Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study." 01/01/2022 - "Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis." 01/01/2018 - "Latanoprostene Bunod 0.024% in Subjects With Open-angle Glaucoma or Ocular Hypertension: Pooled Phase 3 Study Findings."
2.	Ocular Hypertension (Glaucoma, Suspect) 05/01/2018 - "Thus, current evidence indicates once-daily latanoprostene bunod 0.024% is an effective and well tolerated treatment option for the reduction of IOP in adults with OAG or ocular hypertension." 01/01/2018 - "Latanoprostene bunod (LBN) is a topical ophthalmic therapeutic for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension (OHT). " 01/01/2016 - "Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study." 01/01/2022 - "Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis." 01/01/2018 - "Latanoprostene Bunod 0.024% in Subjects With Open-angle Glaucoma or Ocular Hypertension: Pooled Phase 3 Study Findings."
3.	Glaucoma 01/01/2016 - "Critical evaluation of latanoprostene bunod in the treatment of glaucoma." 09/01/2022 - "Use of Latanoprostene Bunod as Adjunctive Glaucoma Therapy in Refractory Glaucoma. " 09/01/2022 - "Use of Latanoprostene Bunod as Adjunctive Glaucoma Therapy in Refractory Glaucoma." 04/01/2020 - "In this review, we summarize NO-mediated therapy for glaucoma, and the state of the art of some NO donating molecules, including latanoprostene bunod in market and some other candidate compounds, for the intervention of glaucoma, as well as prospects and challenges ahead in this field." 01/01/2022 - "A retrospective, multi-center, cohort study of patients with glaucoma treated with netarsudil 0.02% or latanoprostene bunod from five tertiary care centers. "
4.	Low Tension Glaucoma 11/01/2015 - "Studies of latanoprostene bunod in patients diagnosed with normal tension glaucoma are warranted. "
5.	Miosis 07/01/2022 - "Latanoprost and latanoprostene bunod produce similar IOP reduction and miosis in normal canine eyes."

Related Drugs and Biologics

1.	Ophthalmic Solutions (Eye Drops)
2.	Timolol (Blocadren)
3.	Latanoprost (Xalatan)
4.	Nitric Oxide (Nitrogen Monoxide)
5.	Synthetic Prostaglandins (Prostaglandin Analogues)
6.	Prostaglandins
7.	netarsudil
8.	Prostaglandins A
9.	2-methylcyclopentadienyl manganese tricarbonyl (MMT)
10.	BOL 303259-X

Related Therapies and Procedures

1.	Therapeutics
2.	Lasers (Laser)
3.	Topical Administration